Juvena Therapeutics, Inc.

Juvena Therapeutics is a computationally driven biopharma startup discovering and developing biologics for rare and chronic degenerative diseases by mining proteins secreted by human pluripotent stem cells through a machine learning (ML)-enhanced platform. Juvena’s multimodal platform identifies lead therapeutic candidates from a proprietary human embryonic stem cell-derived therapeutic protein library to create organ-specific medicines for chronic and rare diseases. Initial therapeutic programs are advancing leads for muscular dystrophies, muscle atrophy, injury, and osteopathies. Since its launch in mid-2018, Juvena has discovered 17 hits for neuromuscular and skeletal diseases, including several muscle regenerative protein therapeutic candidates with potent human in vitro and mice in vivo efficacy, completed lead optimization on their top drug candidate, and established multiple issued and patent-pending composition of matter formulations. Juvena is advancing a lead program for DM1.